{"id":683,"date":"2024-12-06T17:37:42","date_gmt":"2024-12-06T16:37:42","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/ago-op-6-eclat\/"},"modified":"2026-07-20T17:02:14","modified_gmt":"2026-07-20T15:02:14","slug":"ago-op-6-eclat","status":"publish","type":"post","link":"https:\/\/studienportal-endometriumkrebs.de\/en\/ago-op-6-eclat\/","title":{"rendered":"AGO-OP.6 \u2013 ECLAT"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

AGO-OP.6 \u2013 ECLAT<\/strong><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Study for patients with stage I or II endometrial cancer at high risk of recurrence \u2013 a multicenter, prospective, randomized controlled trial<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

What is being investigated in this study?<\/strong><\/h2>

This study investigates whether removal of the lymph nodes in the pelvis and alongside the abdominal aorta improves overall survival in women with uterine cancer at high risk of recurrence.<\/p>

What is the aim of the study?<\/strong><\/h2>

The study aims to clarify whether the previously standard removal of the lymph nodes in the pelvis and along the abdominal aorta in women with uterine cancer at high risk of recurrence improves the chances of cure (overall survival). If this is the case, this operation should continue to be recommended; if not, it should be omitted in the future.<\/p>

What is the study procedure?<\/strong><\/h2>

The study is being conducted nationwide in Germany at around 55 centers, and a total of 640 patients are to be included. This is a clinical study in which patients undergo surgery and are then followed up for 5 years.<\/p>

It is a prospective, randomized, two-arm, multicenter, open-label study.<\/p>

Eligible patients are randomly assigned to either receive the previously standard lymph node removal or to forgo it. For all patients, given the high risk of recurrence, vaginal radiotherapy (brachytherapy) and chemotherapy (carboplatin\/paclitaxel) are recommended as adjuvant treatment after surgery.<\/p>

Are there any risks?<\/strong><\/h2>

You will be informed about possible risks and\/or side effects associated with participation as part of an informed-consent discussion.<\/p>

Eligibility requirements:<\/strong><\/h2>

Women aged 18\u201375 years can participate in this study if the following criteria are met:<\/p>

Excerpt from the inclusion criteria:<\/strong><\/h2>